<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "3: Forwardlooking ", fill: "#00ff7f"},
{source: "3: Forwardlooking ", target: "3: publicly available", fill: "#00ff7f"},
{source: "3: publicly available", target: "3: documents", fill: "#00ff7f"},
{source: "3: documents", target: "3: in other Securities and Exchange Commission ", fill: "#00ff7f"},
{source: "3: in other Securities and Exchange Commission ", target: "3: Commission ", fill: "#00ff7f"},
{source: "3: Commission ", target: "3: stockholders", fill: "#00ff7f"},
{source: "3: stockholders", target: "3: released by us involve known", fill: "#00ff7f"},
{source: "3: released by us involve known", target: "3: unknown risks", fill: "#00ff7f"},
{source: "3: unknown risks", target: "3: uncertainties", fill: "#00ff7f"},
{source: "3: uncertainties", target: "3: factors which could", fill: "#00ff7f"},
{source: "3: factors which could", target: "3: performance financial", fill: "#00ff7f"},
{source: "3: performance financial", target: "3: achievements", fill: "#00ff7f"},
{source: "3: achievements", target: "3: differ from", fill: "#00ff7f"},
{source: "3: differ from", target: "3: performance financial", fill: "#00ff7f"},
{source: "3: Forwardlooking ", target: "4: based upon current conditions", fill: "#ff7518"},
{source: "4: based upon current conditions", target: "4: operations", fill: "#ff7518"},
{source: "4: based upon current conditions", target: "14: future revenues", fill: "#ae2029"},
{source: "14: future revenues", target: "14: also depends on", fill: "#ae2029"},
{source: "14: also depends on", target: "14: continued revenue growth", fill: "#ae2029"},
{source: "14: continued revenue growth", target: "14: revenue from", fill: "#ae2029"},
{source: "14: revenue from", target: "14: hair care products", fill: "#ae2029"},
{source: "14: hair care products", target: "14: skincare products", fill: "#ae2029"},
{source: "14: skincare products", target: "14: revenue stability within", fill: "#ae2029"},
{source: "14: revenue stability within", target: "14: surgical products", fill: "#ae2029"},
{source: "14: future revenues", target: "25: treatments", fill: "#73a9c2"},
{source: "25: treatments", target: "25: psoriasis vitiligo atopic dermatitis", fill: "#73a9c2"},
{source: "25: psoriasis vitiligo atopic dermatitis", target: "25: skincare products", fill: "#73a9c2"},
{source: "25: skincare products", target: "25: surgical laser products", fill: "#73a9c2"},
{source: "25: surgical laser products", target: "25: future products", fill: "#73a9c2"},
{source: "25: future products", target: "25: services may fail", fill: "#73a9c2"},
{source: "25: services may fail", target: "25: gain market acceptance which", fill: "#73a9c2"},
{source: "25: gain market acceptance which", target: "25: could adversely affect", fill: "#73a9c2"},
{source: "25: could adversely affect", target: "25: competitive position", fill: "#73a9c2"},
{source: "25: treatments", target: "32: adequate financing", fill: "#8fbc8f"},
{source: "32: adequate financing", target: "32: services will find sufficient", fill: "#8fbc8f"},
{source: "32: services will find sufficient", target: "32: acceptance", fill: "#8fbc8f"},
{source: "32: acceptance", target: "32: shortterm goals", fill: "#8fbc8f"},
{source: "32: adequate financing", target: "37: reliability", fill: "#5218fa"},
{source: "37: reliability", target: "37: functionality", fill: "#5218fa"},
{source: "37: functionality", target: "37: upgraded such lasers both", fill: "#5218fa"},
{source: "37: upgraded such lasers both", target: "37: United States ", fill: "#5218fa"},
{source: "37: reliability", target: "58: copper peptide compound manufactured", fill: "#a76bcf"},
{source: "58: copper peptide compound manufactured", target: "58: products distributed by", fill: "#a76bcf"},
{source: "58: products distributed by", target: "58: Neutrogena ", fill: "#a76bcf"},
{source: "58: Neutrogena ", target: "58: license agreement", fill: "#a76bcf"},
{source: "58: license agreement", target: "58: expired on", fill: "#a76bcf"},
{source: "58: expired on", target: "58: February ", fill: "#a76bcf"},
{source: "58: copper peptide compound manufactured", target: "START_HERE", fill: "#a76bcf"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Food Distributors</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Oil and Gas Exploration and Production</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Demonstrate</td>
    </tr>
    <tr>
      <td>Bombings</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States">United States</a></td>
      <td>The United States of America (U.S.A. or USA), commonly known as the United States (U.S. or US) or America, is a country primarily located in North America. It consists of 50 states, a federal district, five major unincorporated territories, 326 Indian reservations, and nine minor outlying islands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_Activities_Center">Special Activities Center</a></td>
      <td>The Special Activities Center (SAC) is a division of the Central Intelligence Agency responsible for covert operations and paramilitary operations. The unit was named Special Activities Division (SAD) prior to 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_research">Operations research</a></td>
      <td>Operations research (British English: operational research), often shortened to the initialism OR, is a discipline that deals with the development and application of advanced analytical methods to improve decision-making. It is sometimes considered to be a subfield of mathematical sciences.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emergency_operations_center">Emergency operations center</a></td>
      <td>An emergency operations center (EOC) is a central command and control facility responsible for carrying out the principles of emergency preparedness and emergency management, or disaster management functions at a strategic level during an emergency, and ensuring the continuity of operation of a company, political subdivision or other organization.\nAn EOC is responsible for strategic direction and operational decisions and does not normally directly control field assets, instead leaving tactical decisions to lower commands.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_(mathematics)">Operation (mathematics)</a></td>
      <td>In mathematics, an operation is a function which takes zero or more input values (called operands) to a well-defined output value. The number of operands (also known as arguments) is the arity of the operation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Surgery">Surgery</a></td>
      <td>Surgery is a medical or dental specialty that uses operative manual and instrumental techniques on a person to investigate or treat a pathological condition such as a disease or injury, to help improve bodily function, appearance, or to repair unwanted ruptured areas.\nThe act of performing surgery may be called a surgical procedure, operation, or simply "surgery".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Acceptance">Acceptance</a></td>
      <td>Acceptance in human psychology is a person's assent to the reality of a situation, recognizing a process or condition (often a negative or uncomfortable situation) without attempting to change it or protest it. The concept is close in meaning to acquiescence, derived from the Latin acquiēscere (to find rest in).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Acceptance_testing">Acceptance testing</a></td>
      <td>In engineering and its various subdisciplines, acceptance testing is a test conducted to determine if the requirements of a specification or contract are met. It may involve chemical tests, physical tests, or performance tests.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Acceptance_(novel)">Acceptance (novel)</a></td>
      <td>Acceptance is a 2014 novel by Jeff VanderMeer. It is the last in a series of three books called the Southern Reach Trilogy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Offer_and_acceptance">Offer and acceptance</a></td>
      <td>Offer and acceptance are generally recognised as essential requirements for the formation of a contract, and analysis of their operation is a traditional approach in contract law. The offer and acceptance formula, developed in the 19th century, identifies a moment of formation when the parties are of one mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Self-acceptance">Self-acceptance</a></td>
      <td>Self-acceptance is acceptance of self.\n\n\n== Definition ==\nSelf-acceptance can be defined as:\n\nthe awareness of one's strengths and weaknesses,\nthe realistic (yet subjective) appraisal of one's talents, capabilities, and general worth, and,\nfeelings of satisfaction with one's self despite deficiencies and regardless of past behaviors and choices.According to Shepard, self-acceptance is an individual's satisfaction or happiness with oneself, and is thought to be necessary for good mental health.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fat_acceptance_movement">Fat acceptance movement</a></td>
      <td>The fat acceptance movement, also known as fat pride, fat empowerment, and fat activism, is a social movement seeking to eliminate the social stigma of fatness from social attitudes by pointing out to the general public the social obstacles faced by fat people. Areas of contention include the aesthetic, legal, and medical approaches to people whose bodies are fatter than the social norm.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Acceptance_and_commitment_therapy">Acceptance and commitment therapy</a></td>
      <td>Acceptance and commitment therapy (ACT, typically pronounced as the word "act") is a form of psychotherapy, as well as a branch of clinical behavior analysis. It is an empirically based psychological intervention that uses acceptance and mindfulness strategies along with commitment and behavior-change strategies to increase psychological flexibility.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_acceptance_model">Technology acceptance model</a></td>
      <td>The technology acceptance model (TAM) is an information systems theory that models how users come to accept and use a technology.  \nThe actual system use is the end-point where people use the technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_states_and_territories_of_the_United_States">List of states and territories of the United States</a></td>
      <td>The United States of America is a federal republic consisting of 50 states, a federal district (Washington, D.C., the capital city of the United States), five major territories, and various minor islands. The 48 contiguous states and Washington, D.C., are in North America between Canada and Mexico.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/President_of_the_United_States">President of the United States</a></td>
      <td>The president of the United States (POTUS) is the head of state and head of government of the United States of America. The president directs the executive branch of the federal government and is the commander-in-chief of the United States Armed Forces.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Congress">United States Congress</a></td>
      <td>The United States Congress is the legislature of the federal government of the United States. It is bicameral, being composed of a lower body, the House of Representatives, and an upper body, the Senate.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Navy">United States Navy</a></td>
      <td>The United States Navy (USN) is the maritime service branch of the United States Armed Forces and one of the eight uniformed services of the United States. It is the largest and most powerful navy in the world, with the estimated tonnage of its active battle fleet alone exceeding the next 13 navies combined, including 11 U.S. allies or partner nations as of 2015.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Marine_Corps">United States Marine Corps</a></td>
      <td>The United States Marine Corps (USMC), also referred to as the United States Marines, is the maritime land force service branch of the United States Armed Forces responsible for conducting expeditionary and amphibious operations through combined arms, implementing its own infantry, artillery, aerial, and special operations forces. The U.S. Marine Corps is one of the eight uniformed services of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_dollar">United States dollar</a></td>
      <td>The United States dollar (symbol: $; code: USD; also abbreviated US$ or U.S. Dollar, to distinguish it from other dollar-denominated currencies; referred to as the dollar, U.S. dollar, American dollar, or colloquially buck) is the official currency of the United States and several other countries. The Coinage Act of 1792 introduced the U.S. dollar at par with the Spanish silver dollar, divided it into 100 cents, and authorized the minting of coins denominated in dollars and cents.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Neutrogena">Neutrogena</a></td>
      <td>Neutrogena Corporation trading as Neutrogena, is an American company that markets skin care, hair care and cosmetics owned by parent company Johnson &amp; Johnson and is headquartered in Los Angeles, California. According to product advertising  at their website, Neutrogena products are distributed in more than 70 countries.Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Jennifer_Freeman">Jennifer Freeman</a></td>
      <td>Jennifer Nicole Freeman is an American actress, often credited as Jennifer N. Freeman. She is best known for playing the role of Claire Kyle in the sitcom My Wife and Kids (introduced in season 2) and her film roles in You Got Served (2004), and Johnson Family Vacation (2004).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Kelly_Preston">Kelly Preston</a></td>
      <td>Kelly Kamalelehua Smith (October 13, 1962 – July 12, 2020), known professionally as Kelly Preston, was an American actress and model. She appeared in more than 60 television and film productions, including Mischief (1985), Twins (1988), Jerry Maguire (1996), and For Love of the Game (1999).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Natascha_McElhone">Natascha McElhone</a></td>
      <td>Natascha McElhone (; born Natasha Abigail Taylor, 14 December 1971) is a British actress. She is a graduate of the London Academy of Music and Dramatic Art.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prachi_Desai">Prachi Desai</a></td>
      <td>Prachi Desai (born 12 September 1988)  is an Indian actress who works in Hindi films and television. She started her television career as the lead protagonist in the successful TV drama Kasam Se on Zee TV. She made her Bollywood debut in the 2008 film Rock On!!.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Nomzamo_Mbatha">Nomzamo Mbatha</a></td>
      <td>Nomzamo  Mbatha (born 13 July 1990), is a South African actress, television personality, businesswoman, accountant and human rights activist.\n\n\n== Early life ==\nNomzamo Mbatha was born on 13 July 1990 in KwaMashu Township, approximately 21 kilometres (13 mi), by road, north-west of the city of Durban, in KwaZulu Natal Province and is of Zulu ethnicity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Julie_Bowen">Julie Bowen</a></td>
      <td>Julie Bowen Luetkemeyer (born March 3, 1970) is an American actress. She is best known for starring as Claire Dunphy in the ABC sitcom Modern Family (2009–2020), for which she received critical acclaim and six nominations for the Primetime Emmy Award for Outstanding Supporting Actress in a Comedy Series, winning in 2011 and 2012.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Nicole_Kidman">Nicole Kidman</a></td>
      <td>Nicole Mary Kidman  (born 20 June 1967) is an American and Australian actress and producer. Known for her work across various film and television productions from several genres, she has continuously remained one of the world's highest-paid actresses.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><font color="blue">These     </font>forward-looking statements include, but are not limited to, <font color="blue">statements about</font>     our plans, objectives, <font color="blue">expectations</font> and <font color="blue">intentions</font> and other statements     contained in this Report that are not <font color="blue">historical facts</font></td>
    </tr>
    <tr>
      <td>Forward-looking     statements in this Report or hereafter included in other <font color="blue">publicly available</font>     <font color="blue">documents</font>  filed  with  the Securities and Exchange Commission, or the     Commission,  reports  to our <font color="blue">stockholders</font> and other <font color="blue">publicly available</font>     statements  issued  or <font color="blue">released by us involve known</font> and <font color="blue">unknown risks</font>,     <font color="blue">uncertainties</font>  and other <font color="blue">factors <font color="blue">which could</font></font> cause our actual results,     performance (financial or operating) or <font color="blue">achievements</font> to <font color="blue">differ from</font> the     future  results,  performance (financial or operating) or <font color="blue">achievements</font>     expressed or implied by such forward-looking statements</td>
    </tr>
    <tr>
      <td>Such future results     are based upon <font color="blue">management</font>apstas best estimates <font color="blue">based upon current <font color="blue">conditions</font></font> and     the most recent results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>When used in this Report, the words      &amp;quote expect, &amp;quote   &amp;quote anticipate, &amp;quote   &amp;quote intend, &amp;quote   &amp;quote plan, &amp;quote   &amp;quote believe, &amp;quote   &amp;quote seek, &amp;quote   &amp;quote estimate &amp;quote  and     similar <font color="blue">expressions</font> are <font color="blue">generally</font> intended to identify forward-looking     statements, because these forward-looking statements involve risks and     <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>There are <font color="blue">important factors</font> that could cause actual results     to  differ  <font color="blue">materially</font>  from  those  expressed  or  implied  by  these     forward-looking statements, including our plans, objectives, <font color="blue">expectations</font>     and <font color="blue">intentions</font> and other <font color="blue">factors discussed</font> in the risk factors, described     below</td>
    </tr>
    <tr>
      <td>18       _________________________________________________________________       Risks Related to Our Business           We have a history of losses, expect <font color="blue">future losses</font> and <font color="blue">cannot assure</font> you that     we will become or <font color="blue">remain profitable</font></td>
    </tr>
    <tr>
      <td>Historically, we have <font color="blue">incurred <font color="blue">significant</font> losses</font> and have had <font color="blue">negative cash</font>     <font color="blue">flows from</font> our <font color="blue">phototherapy</font> <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">surgical products</font> and services     business  also  has <font color="blue">generated losses</font> in <font color="blue">recent years</font></td>
    </tr>
    <tr>
      <td>To date, we have     <font color="blue">dedicated most</font> of our <font color="blue">financial resources</font> to research and <font color="blue">development</font> and     selling, general and <font color="blue">administrative expenses</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, our     <font color="blue">accumulated deficit</font> was <font color="blue">approximately</font> dlra80dtta2 million</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future revenues</font> and <font color="blue">success depend <font color="blue">significant</font>ly upon <font color="blue">acceptance</font></font> of our     <font color="blue">excimer <font color="blue">laser systems</font></font> for the <font color="blue">treatment principally</font> of psoriasis, but also     of vitiligo, atopic <font color="blue">dermatitis</font> and leukoderma</td>
    </tr>
    <tr>
      <td><font color="blue">Our XTRAC </font>system for the     treatment of these <font color="blue">conditions</font> generates revenues, but those revenues are     presently insufficient to generate positive cash <font color="blue">flows from</font> our <font color="blue">operations</font>     in the two XTRAC-related business segments</td>
    </tr>
    <tr>
      <td>Our <font color="blue">future revenues</font> and success     <font color="blue">also depends on</font> the <font color="blue">continued <font color="blue">revenue growth</font></font> of the <font color="blue">revenue from</font> the skin     health and <font color="blue">hair care products</font> of our <font color="blue">skincare products</font> and of our surgical     services  business  and <font color="blue">revenue stability within</font> our <font color="blue">surgical products</font>     business</td>
    </tr>
    <tr>
      <td>Our ability to market our products and <font color="blue">services successfully</font> and     the expected benefits to be obtained from our products and <font color="blue">services may</font> be     <font color="blue"><font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font> by</font> a number of factors, such as unforeseen costs and     expenses, technological changes, economic downturns, <font color="blue">competitive</font> factors or     other <font color="blue">events beyond</font> our control</td>
    </tr>
    <tr>
      <td>We expect to incur losses as we move into fiscal 2006 because we plan to     spend  substantial  amounts  on  expanding, in <font color="blue">controlled fashion</font>, our     <font color="blue">operations</font> in <font color="blue">phototherapy</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that we will market any     <font color="blue">products successfully</font>, operate profitably in the future, or that we will not     require <font color="blue"><font color="blue">significant</font> <font color="blue">additional financing</font></font> in order to accomplish our business     plan</td>
    </tr>
    <tr>
      <td>We may need <font color="blue">additional financing</font> to maintain and expand our business, and     <font color="blue"><font color="blue">such financing</font> may</font> not be <font color="blue">available on</font> favorable terms, if at all</td>
    </tr>
    <tr>
      <td>We  have  <font color="blue">historically financed</font> our <font color="blue">activities through</font> working capital     provided from <font color="blue">operations</font>, the <font color="blue">private placement</font> of <font color="blue">equity securities</font> and     from lines of credit</td>
    </tr>
    <tr>
      <td>We believe that our cash balance, together with access     to <font color="blue">lease financing</font> for <font color="blue">capital expenditures</font> and other <font color="blue">existing financial</font>     resources,  and  revenues  from  sales,  <font color="blue">distribution</font>,  licensing  and     <font color="blue">manufacturing</font> relationships, should be sufficient to meet our operating and     <font color="blue"><font color="blue">capital <font color="blue">requirements</font></font> into</font> the <font color="blue">second quarter</font> of 2007</td>
    </tr>
    <tr>
      <td>However, we may have     to raise substantial <font color="blue">additional capital</font> if:           ·     operating <font color="blue">losses continue</font>, if anticipated demand for the XTRAC system for     the treatment of psoriasis or <font color="blue">surgical <font color="blue">laser systems</font></font> do not meet our current     <font color="blue">expectations</font>;           ·     we fail to maintain existing or develop <font color="blue">new customers</font> or <font color="blue">corporate partners</font>     for the marketing and <font color="blue">distribution</font> of our <font color="blue">skincare products</font>;           ·     the <font color="blue">geographic expansion</font> of our <font color="blue">surgical services</font> is <font color="blue">stymied by <font color="blue">competition</font></font>     and <font color="blue">revenue increases</font> do not <font color="blue">materialize</font>;           ·     we need to maintain or <font color="blue">accelerate</font> favorable, but costlier, growth of our     revenues; or           ·     changes in our research and <font color="blue">development</font> plans <font color="blue">necessitate unexpected</font>, large     <font color="blue">future expenditures</font></td>
    </tr>
    <tr>
      <td>If we need <font color="blue">additional financing</font>, we <font color="blue">cannot assure</font> you that <font color="blue">such financing</font>     will be <font color="blue">available on</font> favorable terms, if at all</td>
    </tr>
    <tr>
      <td>In addition, any future     <font color="blue">issuance may</font> result in substantial dilution to existing <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>If we     need funds and <font color="blue">cannot raise them on</font> acceptable terms, we may not be able to:           ·     execute our growth plan for the XTRAC system, <font color="blue">surgical services</font> and skincare     products;           ·     expand our <font color="blue"><font color="blue">manufacturing</font> facilities</font>, if <font color="blue">necessary</font>, <font color="blue">based on</font> increased demand     for the XTRAC system or other <font color="blue">surgical products</font> or new <font color="blue">skincare products</font>,     which may be introduced;           ·     take advantage of <font color="blue">future opportunities</font>, including <font color="blue">synergistic <font color="blue">acquisition</font>s</font>;           ·     respond to customers, <font color="blue"><font color="blue">competitor</font>s</font> or violators of our <font color="blue">proprietary</font> and     <font color="blue">contractual rights</font>; or           ·     remain in operation</td>
    </tr>
    <tr>
      <td>19       _________________________________________________________________       Our  laser  <font color="blue">treatments</font>  of  psoriasis, vitiligo, atopic <font color="blue">dermatitis</font> and     leukoderma, our <font color="blue">skincare products</font> and our <font color="blue">surgical laser products</font> and any of     our <font color="blue">future products</font> or <font color="blue">services may</font> fail to <font color="blue">gain market <font color="blue">acceptance</font></font>, which     <font color="blue">could <font color="blue"><font color="blue">adversely</font> affect</font></font> our <font color="blue"><font color="blue">competitive</font> position</font></td>
    </tr>
    <tr>
      <td>No  <font color="blue">in<font color="blue">dependent</font> studies with</font> regard to the <font color="blue">feasibility</font> of our proposed     business plan have <font color="blue">been conducted by <font color="blue">third parties</font> with respect</font> to our     present and future business prospects and <font color="blue">capital <font color="blue">requirements</font></font></td>
    </tr>
    <tr>
      <td>We have     generated limited commercial <font color="blue">distribution</font> for our XTRAC system and our other     products</td>
    </tr>
    <tr>
      <td>Skincare products sales are <font color="blue"><font color="blue">dependent</font> on existing strategic</font>     partners for <font color="blue">distributing</font> and marketing its products</td>
    </tr>
    <tr>
      <td>We may be <font color="blue">unsuccessful</font>     in <font color="blue">continuing existing</font> or developing <font color="blue">new strategic partners</font> in order to     maintain or expand the markets for the skincare business’ existing or future     products</td>
    </tr>
    <tr>
      <td>Our surgical <font color="blue">services may</font> fail to <font color="blue">gain market <font color="blue">acceptance</font></font> in new     <font color="blue">territories into which</font> we expand</td>
    </tr>
    <tr>
      <td>In addition, our infrastructure to enable     such expansion, though stronger than in the past, is still limited</td>
    </tr>
    <tr>
      <td>Even if     <font color="blue">adequate financing</font> is available and our products are ready for market, we     cannot  assure you that our products and <font color="blue">services will find sufficient</font>     <font color="blue">acceptance</font> in the marketplace to fulfill our long and short-term goals</td>
    </tr>
    <tr>
      <td>We     <font color="blue">cannot assure</font> you that the <font color="blue">marketplace will</font> be receptive to our excimer     laser <font color="blue">technology</font>, <font color="blue">skincare products</font>, or our <font color="blue">surgical services</font> over competing     products, services and therapies or that a cure will not be found for the     <font color="blue">underlying diseases</font> we are <font color="blue">focused on treating</font></td>
    </tr>
    <tr>
      <td>Failure of our products and     <font color="blue">surgical services</font> to achieve market <font color="blue">acceptance</font> could have a material adverse     effect on our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>While we have engaged in <font color="blue">clinical studies</font> for our <font color="blue">psoriasis treatment</font>, and     based  on these studies, we have gained FDA clearance, <font color="blue">appropriate</font> CPT     <font color="blue"><font color="blue">reimbursement</font> codes</font> for treatment and <font color="blue">suitable <font color="blue"><font color="blue">reimbursement</font> rates</font> from</font> CMS     for those codes, we may face other hurdles to market <font color="blue">acceptance</font> if, for     example,  <font color="blue">practitioners</font> in <font color="blue">significant</font> numbers wait to see longer-term     studies or if it becomes <font color="blue">necessary</font> to conduct studies <font color="blue">corroborating</font> the role     <font color="blue">of the XTRAC </font>system as a second-line therapy for <font color="blue">treating psoriasis</font> or if     patients do not elect to undergo <font color="blue">psoriasis treatment</font> using the XTRAC system</td>
    </tr>
    <tr>
      <td>We have not had sufficient time to observe the long-term <font color="blue">effective</font>ness or     potential side effects of our treatment system for psoriasis, vitiligo,     atopic  <font color="blue">dermatitis</font> or <font color="blue">leukoderma nor</font> to gauge what marketing and sales     programs, if any, are <font color="blue">effective</font> in increasing patients’ demand for the     treatment of <font color="blue">psoriasis with</font> the XTRAC system</td>
    </tr>
    <tr>
      <td>In 2003, we improved the <font color="blue">re<font color="blue">liability</font></font> and <font color="blue">functionality</font> <font color="blue">of the XTRAC </font>system     and <font color="blue">upgraded such lasers both</font> in the <font color="blue"><font color="blue">United States</font> </font>and overseas</td>
    </tr>
    <tr>
      <td>In 2004, we     obtained FDA 510(k) marketing clearance for a smaller and faster <font color="blue">XTRAC     </font>system  known  as  the Ultra</td>
    </tr>
    <tr>
      <td>These <font color="blue">efforts should help us gain market</font>     <font color="blue">acceptance</font> for the XTRAC <font color="blue">system both</font> in the <font color="blue"><font color="blue">United States</font> </font>and abroad, but do     not guarantee such <font color="blue">acceptance</font> or that we may not encounter further problems     in <font color="blue">re<font color="blue">liability</font></font></td>
    </tr>
    <tr>
      <td>We have designed the XTRAC system to be user-friendly, such     that a properly in-serviced medical technician in a physician’s office may,     under  the  physician’s supervision, safely and <font color="blue">effective</font>ly administer     <font color="blue">treatments</font> to a patient</td>
    </tr>
    <tr>
      <td>In fact, the CMS <font color="blue"><font color="blue">reimbursement</font> rates</font> are <font color="blue">based on</font>     the  <font color="blue">lower labor rates</font> achieved <font color="blue">through <font color="blue">such <font color="blue">delegation</font></font></font></td>
    </tr>
    <tr>
      <td>Nevertheless,     whether a <font color="blue">treatment may</font> be delegated, and if so to whom and to what extent,     are matters that may vary state by state, as these matters are within the     province of the state <font color="blue">medical boards</font></td>
    </tr>
    <tr>
      <td>In states that may be more <font color="blue">restrictive</font>     in <font color="blue">such <font color="blue">delegation</font></font>, a <font color="blue">physician may decline</font> to adopt the XTRAC <font color="blue">system into</font>     his  or  her practice, deeming it to be too much <font color="blue">fraught with too</font> many     <font color="blue">constraints</font> and finding other outlets for the physician’s time and staff     time to be more <font color="blue">remunerative</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that we will be     successful in persuading such <font color="blue">medical boards</font> that a liberal standard for     <font color="blue">delegation</font> is <font color="blue">appropriate</font> for the XTRAC system, given its design for ease     and safety of use</td>
    </tr>
    <tr>
      <td>If we are not successful, we may find that even if a     <font color="blue">geographic region</font> has <font color="blue">wide insurance <font color="blue">reimbursement</font></font>, the region’s physicians     <font color="blue">may yet balk at adopting</font> the XTRAC <font color="blue">system into</font> their practices</td>
    </tr>
    <tr>
      <td>Our success is <font color="blue"><font color="blue">dependent</font> on <font color="blue"><font color="blue">intellectual</font> property rights</font></font> held by us, and our     business will be <font color="blue"><font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font> by</font> direct <font color="blue">competition</font> if we are unable     to protect these rights</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success will depend</font>, in part, on our ability to maintain and defend our     patents</td>
    </tr>
    <tr>
      <td>However, we <font color="blue">cannot give</font> you any assurances that the <font color="blue">technologies</font>     and <font color="blue">processes <font color="blue">covered by</font></font> all of our patents may not be found to be obvious     or <font color="blue">substantially</font> similar to prior work, <font color="blue">which could</font> render these patents     unenforceable</td>
    </tr>
    <tr>
      <td>Moreover, as our patents expire, <font color="blue"><font color="blue"><font color="blue">competitor</font>s</font> may utilize</font> the     <font color="blue"><font color="blue">technology</font> found</font> in <font color="blue">such patents</font> to <font color="blue">commercialize</font> their own <font color="blue">laser systems</font></td>
    </tr>
    <tr>
      <td>In offset to the <font color="blue">expiring patents</font>, we endeavor to <font color="blue">secure additional patents</font>     on critical, commercially desirable improvements to the <font color="blue">inventions</font> of the     <font color="blue">expiring patents</font></td>
    </tr>
    <tr>
      <td>There can be no assurance that we will be successful in     <font color="blue">securing such additional patents</font>, or that <font color="blue">such additional patents will</font>     <font color="blue">adequately offset</font> the effect of the <font color="blue">expiring patents</font></td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________       Of  particular  note  is US Patent Nodtta 4cmam891cmam818, the so-called “ ‘818     Patent”, which covers, among other things, the design of the gas chamber in     the XTRAC system</td>
    </tr>
    <tr>
      <td>The ‘818 Patent will expire on August 31, 2007 and will     thereafter  no  longer  serve  as a barrier to entry to the <font color="blue">relatively</font>     <font color="blue">reimbursement</font>-rich US market</td>
    </tr>
    <tr>
      <td>The <font color="blue">additional patent rights</font> we <font color="blue">seek may serve</font>     less to <font color="blue">bar <font color="blue"><font color="blue">competitor</font>s</font> from entry</font> and may serve more, when <font color="blue">aggregated with</font>     other clinical and <font color="blue"><font color="blue">competitive</font> strengths</font>, to differentiate and distinguish     our  product  (eg  the  Ultra), in both its utility and its range of     <font color="blue">applications</font>, from those of <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">may therefore choose</font> in the US     market to broaden our fee-per-procedure business model to include a direct     sales  option, as we have done and continue to do in the <font color="blue">international</font>     market</td>
    </tr>
    <tr>
      <td>Where a <font color="blue">competitor</font> infringes on our patent and other <font color="blue">proprietary</font>     rights, we are prepared, our <font color="blue"><font color="blue">financial condition</font> permitting</font>, to defend those     <font color="blue">rights vigorously</font> in the US courts</td>
    </tr>
    <tr>
      <td>If we <font color="blue">unable through</font> these <font color="blue">innovations</font>     to preserve our <font color="blue">proprietary</font> rights, our ability to market the XTRAC system     could be <font color="blue">materially</font> and <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td>A US patent relating to a <font color="blue"><font color="blue">copper peptide compound</font> <font color="blue">manufacture</font>d</font> and used in     <font color="blue">products distributed by</font> <font color="blue">Neutrogena </font>under the <font color="blue">Neutrogena </font><font color="blue">license <font color="blue">agreement</font></font>     <font color="blue">expired on</font> <font color="blue">February </font>5, 2005</td>
    </tr>
    <tr>
      <td>Upon expiration of this patent, the <font color="blue">agreement</font>     specifies that <font color="blue">lower royalty <font color="blue">percentages</font> from sales</font> of <font color="blue">such products</font> be used     for the <font color="blue">remaining term</font>, the impact of which is a reduction in the average     <font color="blue">effective</font> royalty rate of <font color="blue">approximately</font> 50prca</td>
    </tr>
    <tr>
      <td>The <font color="blue">actual amount</font> of royalty     income  recognized  in  future  periods  is <font color="blue"><font color="blue">dependent</font> upon</font> the royalty     <font color="blue">percentages</font> in effect during the period and the <font color="blue">actual applicable sales</font>     reported  by  Neutrogena,  which can <font color="blue">vary from quarter</font> to quarter</td>
    </tr>
    <tr>
      <td>The     expiration of the patent would also allow others, including Neutrogena, to     apply the <font color="blue">technology</font> <font color="blue">covered by</font> that patent in their products</td>
    </tr>
    <tr>
      <td>Trade secrets and other <font color="blue">proprietary</font> information which are not <font color="blue">protected by</font>     patents are <font color="blue">also critical</font> to our business</td>
    </tr>
    <tr>
      <td>We attempt to protect our trade     secrets by entering into confidentiality <font color="blue">agreement</font>s with <font color="blue">third parties</font>,     employees and <font color="blue">consultants</font></td>
    </tr>
    <tr>
      <td>However, these <font color="blue">agreement</font>s can be breached and, if     they are and even if we are able to prove the breach or that our <font color="blue">technology</font>     has been mis<font color="blue">appropriate</font>d under applicable state law, there may not be an     adequate  remedy  available  to  us</td>
    </tr>
    <tr>
      <td>In  addition,  it  is costly and     time-consuming <font color="blue">litigation</font> may be <font color="blue">necessary</font> to enforce and determine the     scope of our <font color="blue">proprietary</font> rights, and even if we prevail in <font color="blue">litigation</font>, the     party  we <font color="blue">prevail over may</font> have <font color="blue">scant resources available</font> to satisfy a     judgment</td>
    </tr>
    <tr>
      <td>Further, our skin care business seeks to <font color="blue">establish customer loyalty</font>, to in     part, by means of our use of <font color="blue">trademarks</font></td>
    </tr>
    <tr>
      <td>It can be <font color="blue">difficult</font> and costly to     defend <font color="blue">trademarks</font> from encroachment or <font color="blue">misappropriation overseas</font></td>
    </tr>
    <tr>
      <td><font color="blue">Third     </font><font color="blue">parties may also challenge</font> the validity of certain of our <font color="blue">trademarks</font></td>
    </tr>
    <tr>
      <td>In     <font color="blue">either eventuality</font>, our <font color="blue">customers may become confused</font> and direct their     purchases to <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may in<font color="blue">dependent</font>ly discover trade secrets</font> and <font color="blue">proprietary</font>     information that <font color="blue">allow them</font> to develop <font color="blue">technologies</font> and products that are     <font color="blue">substantially</font> equivalent or superior to our own</td>
    </tr>
    <tr>
      <td>Without the protection     afforded by our patent, trade secret and <font color="blue">proprietary</font> information rights, we     may face direct <font color="blue">competition</font> from others <font color="blue">commercializing</font> their products using     our <font color="blue">technology</font>, which may have a material adverse effect on our business and     our prospects</td>
    </tr>
    <tr>
      <td><font color="blue">Defending  </font>against  <font color="blue"><font color="blue">intellectual</font> property infringement</font> claims could be     time-consuming and expensive, and if we are not successful, could cause     substantial expenses and disrupt our business</td>
    </tr>
    <tr>
      <td>We cannot be sure that the products, services, <font color="blue">technologies</font> and <font color="blue">advertising</font>     we  employ  in our business do not or will not <font color="blue">infringe valid patents</font>,     <font color="blue">trademarks</font>, copyrights or other <font color="blue"><font color="blue">intellectual</font> property rights</font> held by third     parties</td>
    </tr>
    <tr>
      <td>We may be subject in the <font color="blue">ordinary course</font> of our business to legal     <font color="blue">proceedings</font>  and claims from time to time relating to the <font color="blue">intellectual</font>     property of others</td>
    </tr>
    <tr>
      <td>Any <font color="blue">legal action against us</font> claiming damages or seeking     to <font color="blue">enjoin commercial activities</font> relating to the <font color="blue">affected products</font> or our     methods or processes could have a material adverse effect on our business     and <font color="blue">prospects by</font>:           21       _________________________________________________________________           ·     requiring us, or our <font color="blue">collaborators</font>, to obtain a license to continue to use,     <font color="blue">manufacture</font> or market the <font color="blue">affected products</font>, methods or processes, and such     a <font color="blue">license may</font> not be <font color="blue">available on</font> commercially reasonable terms, if at all;           ·     <font color="blue">preventing us from</font> making, using or selling the subject matter claimed in     patents held by others and subject us to <font color="blue">potential <font color="blue">liability</font></font> for damages;           ·     consuming a substantial portion of our managerial and <font color="blue">financial resources</font>;     or           ·     resulting in <font color="blue">litigation</font> or administrative <font color="blue">proceedings</font> that may be costly,     whether we win or lose</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> on third-party <font color="blue">reimbursement</font> of patients &amp;apos  costs for our     XTRAC system, <font color="blue">which could</font> result in <font color="blue">potentially reduced prices</font> or reduced     demand</td>
    </tr>
    <tr>
      <td>Our  ability  to  market the XTRAC system and other <font color="blue">treatment products</font>     <font color="blue">successfully will depend</font> in large part on the extent to <font color="blue">which various third</font>     parties are willing to <font color="blue">reimburse patients</font> or providers for the costs of     medical procedures utilizing <font color="blue">such products</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">third parties</font> include     government authorities, private health insurers and other <font color="blue"><font color="blue">organization</font>s</font>,     such  as  health  maintenance  <font color="blue"><font color="blue">organization</font>s</font></td>
    </tr>
    <tr>
      <td>Third-party  payers are     <font color="blue">systematically challenging</font> the <font color="blue">prices charged</font> for <font color="blue">medical products</font> and     services</td>
    </tr>
    <tr>
      <td>They <font color="blue">may deny <font color="blue">reimbursement</font></font> if they determine that a prescribed     device is not used in <font color="blue">accordance with</font> cost-<font color="blue">effective</font> treatment methods as     determined by the payer, or is experimental, un<font color="blue">necessary</font> or in<font color="blue">appropriate</font></td>
    </tr>
    <tr>
      <td>Further, although third-parties may approve <font color="blue">reimbursement</font>, such approvals     may be <font color="blue">under terms</font> and <font color="blue">conditions</font> that <font color="blue">discourage use</font> <font color="blue">of the XTRAC </font>laser     system</td>
    </tr>
    <tr>
      <td>Accordingly, if <font color="blue">less costly drugs</font> or other <font color="blue">treatments</font> are available,     third-party payers may not authorize or <font color="blue">may limit <font color="blue">reimbursement</font></font> for the use     of its products, even if our products are safer or more <font color="blue">effective</font> than the     <font color="blue"><font color="blue">alternative</font>s</font></td>
    </tr>
    <tr>
      <td>Although we have received <font color="blue"><font color="blue">reimbursement</font> approvals from</font> an increased number     of private healthcare plans, we <font color="blue">cannot give</font> assurance that private plans     <font color="blue">will continue</font> to adopt or maintain favorable <font color="blue"><font color="blue">reimbursement</font> policies</font> or to     accept the XTRAC system in its <font color="blue">clinical role as</font> a second-line therapy in the     treatment of psoriasis</td>
    </tr>
    <tr>
      <td>Additionally, <font color="blue">third party payers may</font> require further     <font color="blue">clinical studies</font> or changes to our <font color="blue">pricing structure</font> and <font color="blue">revenue model</font>     before <font color="blue">authorizing <font color="blue">reimbursement</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">As of March </font>16, 2006, we estimate, <font color="blue">based on</font> published coverage policies and     <font color="blue">on payment practices</font> of private and Medicare insurance plans, that more than     75prca  of the <font color="blue">insured population</font> in the <font color="blue"><font color="blue">United States</font> </font>are <font color="blue">covered by</font> the     <font color="blue">insurance coverage</font> or <font color="blue">payment policies</font> that <font color="blue">reimburse physicians</font> for using     the XTRAC system for treatment of psoriasis</td>
    </tr>
    <tr>
      <td>Based on these reports and     estimates, we are continuing the <font color="blue">implementation</font> of a <font color="blue">rollout strategy</font> for     the XTRAC system in the <font color="blue"><font color="blue">United States</font> </font>in selected areas of the country where     <font color="blue">reimbursement</font> is <font color="blue">widely available</font></td>
    </tr>
    <tr>
      <td>The success of the <font color="blue">rollout depends on</font>     <font color="blue">increasing physician</font> and <font color="blue">patient demand</font> for the treatment</td>
    </tr>
    <tr>
      <td>We can give no     assurance that <font color="blue">health insurers will</font> not <font color="blue"><font color="blue">adversely</font> modify</font> their <font color="blue">reimbursement</font>     policies for the use <font color="blue">of the XTRAC </font>system in the future</td>
    </tr>
    <tr>
      <td>We intend to <font color="blue">seek coverage</font> and <font color="blue">reimbursement</font> for the use <font color="blue">of the XTRAC </font>system     to  treat other <font color="blue">inflammatory skin disorders</font>, after <font color="blue">additional clinical</font>     studies  are  completed</td>
    </tr>
    <tr>
      <td>There can be <font color="blue">no assurances</font> that we will be in     position to <font color="blue">expand coverage</font> for vitiligo or to seek <font color="blue">reimbursement</font> for the     use <font color="blue">of the XTRAC </font>system to treat atopic <font color="blue">dermatitis</font> or leukoderma, or, if we     do, that any <font color="blue">health insurers will</font> agree to any <font color="blue">reimbursement</font> policy</td>
    </tr>
    <tr>
      <td>Cost <font color="blue">containment measures</font> and any <font color="blue">general <font color="blue">healthcare reform</font> could <font color="blue">adversely</font></font>     affect our ability to market our products</td>
    </tr>
    <tr>
      <td>Cost <font color="blue">containment measures</font> instituted by healthcare providers and insurers     and  any <font color="blue">general <font color="blue">healthcare reform</font> could affect</font> our ability to receive     <font color="blue">revenue from</font> the use of our XTRAC system or to market our <font color="blue">skincare products</font>,     and <font color="blue">surgical laser products</font>, and may have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> the effect of <font color="blue">future legislation</font> or <font color="blue">regulation concerning</font>     the <font color="blue">healthcare industry</font> and third-party coverage and <font color="blue">reimbursement</font> on our     business</td>
    </tr>
    <tr>
      <td>In addition, fundamental reforms in the <font color="blue">healthcare industry</font> in the     <font color="blue"><font color="blue">United States</font> </font>and the EU continue to be considered, although we cannot     <font color="blue">predict whether</font> or when any <font color="blue"><font color="blue">healthcare reform</font> proposals will</font> be adopted and     what <font color="blue">impact such proposals might</font> have on demand for our products</td>
    </tr>
    <tr>
      <td><font color="blue">The XTRAC </font>system <font color="blue">will continue</font> to be the <font color="blue">most promising product</font> that is     <font color="blue">currently marketed</font></td>
    </tr>
    <tr>
      <td>If physicians do not adopt the XTRAC system, we will not     achieve anticipated <font color="blue">revenue growth</font></td>
    </tr>
    <tr>
      <td>22       _________________________________________________________________       We <font color="blue">commercially introduced</font> the XTRAC system in August 2000, but decelerated     that <font color="blue">introduction while</font> we sought <font color="blue">appropriate</font> CPT codes and <font color="blue">suitable rates</font>     of <font color="blue">reimbursement</font> from CMS After we obtained CPT codes and <font color="blue">reimbursement</font>     <font color="blue">rates from</font> <font color="blue">CMS for the CPT </font>codes, we began a <font color="blue">rollout strategy</font> for the <font color="blue">XTRAC     </font>system in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>To achieve <font color="blue">increasing revenue</font>, this product     <font color="blue">must also gain <font color="blue">recognition</font></font> and <font color="blue">adoption by physicians</font> who <font color="blue">treat psoriasis</font>     and  other  skin  disorders</td>
    </tr>
    <tr>
      <td><font color="blue">The XTRAC </font><font color="blue">system represents</font> a <font color="blue">significant</font>     departure from <font color="blue">conventional</font> <font color="blue">psoriasis treatment</font> methods</td>
    </tr>
    <tr>
      <td>We believe that the     <font color="blue">recognition</font> and adoption <font color="blue">of the XTRAC </font><font color="blue">system would</font> be expedited if there     were long-term <font color="blue">clinical data</font> demonstrating that the XTRAC <font color="blue">system provides</font> an     <font color="blue">effective</font> and <font color="blue">attractive <font color="blue">alternative</font></font> to <font color="blue">conventional</font> means of treatment for     psoriasis</td>
    </tr>
    <tr>
      <td>Currently, however, there are <font color="blue">still only</font> limited peer-reviewed     clinical reports and short-term clinical follow-up data on the XTRAC system</td>
    </tr>
    <tr>
      <td><font color="blue">Physicians </font>are <font color="blue">traditionally cautious</font> in <font color="blue">adopting <font color="blue">new products</font></font> and treatment     practices,  partially  due  to the <font color="blue">anticipation</font> of <font color="blue"><font color="blue">liability</font> risks</font> and     <font color="blue">partially due</font> to <font color="blue">uncertainty</font> of third-party <font color="blue">reimbursement</font></td>
    </tr>
    <tr>
      <td>If physicians do     not adopt the XTRAC system, we may never achieve <font color="blue">significant</font> revenues or     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>If  the  <font color="blue">effective</font>ness and safety of our products are not <font color="blue">supported by</font>     long-term data, our <font color="blue">revenues could decline</font></td>
    </tr>
    <tr>
      <td>Our  products  may  not be accepted if we do not produce <font color="blue">clinical data</font>     <font color="blue">supported by</font> the <font color="blue">in<font color="blue">dependent</font> efforts</font> of <font color="blue">clinicians</font></td>
    </tr>
    <tr>
      <td>We received clearance     from the FDA for the use <font color="blue">of the XTRAC </font>system to <font color="blue">treat psoriasis</font> based upon     our  study  of  a limited number of patients</td>
    </tr>
    <tr>
      <td>Safety and efficacy data     presented to the FDA for the XTRAC system was <font color="blue">based on</font> studies on these     patients</td>
    </tr>
    <tr>
      <td>For the treatment of vitiligo, atopic <font color="blue">dermatitis</font> and leukoderma,     we have received clearance from the FDA for the use <font color="blue">of the XTRAC </font>system     <font color="blue">based primarily on equivalence</font> of <font color="blue">predicate devices</font>; we <font color="blue">may discover</font> that     <font color="blue">physicians will</font> expect <font color="blue">clinical data</font> on such <font color="blue">treatments</font> with the <font color="blue">XTRAC     </font>system</td>
    </tr>
    <tr>
      <td>We may find that data from longer-term psoriasis patient follow-up     studies  may  be  <font color="blue">inconsistent</font>  with those <font color="blue">indicated by</font> our <font color="blue">relatively</font>     short-term data</td>
    </tr>
    <tr>
      <td>If longer-term patient studies or clinical experience     indicate that <font color="blue">treatment with</font> the XTRAC system does not <font color="blue">provide patients with</font>     <font color="blue">sustained benefits</font> or that <font color="blue">treatment with</font> our product is less <font color="blue">effective</font> or     <font color="blue">less safe than</font> our <font color="blue">current data</font> suggests, our <font color="blue">revenues could decline</font></td>
    </tr>
    <tr>
      <td>We can     <font color="blue">give no assurance</font> that we may find that our data is not <font color="blue">substantiated</font> in     studies  involving  more patients; in such a case we may never achieve     <font color="blue">significant</font> revenues or <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Any failure in our physician education efforts could <font color="blue">significant</font>ly reduce     <font color="blue">product marketing</font></td>
    </tr>
    <tr>
      <td>It  is  important  to  the success of our <font color="blue">marketing efforts</font> to educate     physicians and <font color="blue">technicians</font> in the <font color="blue">techniques</font> of using the XTRAC system</td>
    </tr>
    <tr>
      <td>We     <font color="blue">rely on physicians</font> to spend their time and money to attend our pre-sale     <font color="blue">educational sessions</font></td>
    </tr>
    <tr>
      <td>Positive results using the XTRAC system are highly     <font color="blue"><font color="blue">dependent</font> upon</font> proper physician and <font color="blue">technician technique</font></td>
    </tr>
    <tr>
      <td>If physicians and     <font color="blue">technicians</font> use the XTRAC <font color="blue">system improperly</font>, they may have unsatisfactory     <font color="blue">patient outcomes</font> or cause patient injury, which may give rise to negative     publicity or <font color="blue">lawsuits against us</font>, any of <font color="blue">which could</font> have a material adverse     effect on our <font color="blue">reputation as</font> a medical device company and our revenues and     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Similarly, it is important to our success that we educate and persuade     hospitals, surgery centers and <font color="blue">practitioners</font> of the clinical and economic     benefits of our <font color="blue">surgical products</font> and services</td>
    </tr>
    <tr>
      <td>If we fail to educate and     persuade our customers, we <font color="blue">may suffer <font color="blue">adversely</font></font> in our reputation and our     revenues and our <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">revenue from</font> a <font color="blue">significant</font> customer continues to decline, we may have     <font color="blue">difficult</font>y replacing the <font color="blue">lost revenue</font></td>
    </tr>
    <tr>
      <td>Neutrogena, one of the customers for the skin health and <font color="blue">hair care products</font>     segment that we acquired from ProCyte, <font color="blue">accounts</font> for a <font color="blue">significant</font> portion of     our  net revenue in that business segment</td>
    </tr>
    <tr>
      <td>ProCyte’s <font color="blue">net revenues from</font>     <font color="blue">Neutrogena </font>in 2004 were dlra2cmam768cmam072, or <font color="blue">approximately</font> 20dtta8prca of ProCyte’s     gross revenues of dlra13cmam320cmam200 (revenues which pre-date our <font color="blue">acquisition</font> and     which are not reflected in our <font color="blue">financial statements</font>), and for the year ended     <font color="blue">December </font>31, 2005, Skin Care’s (ProCyte) <font color="blue">net revenues from</font> <font color="blue">Neutrogena </font>were     dlra1cmam421cmam946, or <font color="blue">approximately</font> 10dtta9prca of Skin Care’s (ProCyte) gross revenues     of dlra13cmam011cmam694 (revenues which are reflected in our <font color="blue">financial statements</font> to     the extent that they were <font color="blue">earned since</font> March 19, 2005)</td>
    </tr>
    <tr>
      <td>We receive royalty     <font color="blue">revenues on sales</font> of <font color="blue">products by</font> <font color="blue">Neutrogena </font>under the terms of a license     <font color="blue">agreement</font> with Neutrogena</td>
    </tr>
    <tr>
      <td>The <font color="blue">royalties from</font> <font color="blue">Neutrogena </font>for 2004 and for     the  year  ended  <font color="blue">December </font> 31,  2005,  were  dlra1cmam214cmam073 and dlra609cmam946,     <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">license <font color="blue">agreement</font></font> expires in April 2010</td>
    </tr>
    <tr>
      <td>A US patent     related to the <font color="blue">Neutrogena </font><font color="blue">license <font color="blue">agreement</font></font> expired <font color="blue">February </font>5, 2005, the     effect of which was a reduction in the <font color="blue">percentage paid as</font> a <font color="blue">royalty during</font>     the <font color="blue">remaining royalty period under</font> the <font color="blue">license <font color="blue">agreement</font></font></td>
    </tr>
    <tr>
      <td>We also receive     <font color="blue">revenues from sales</font> of <font color="blue">copper peptide compound</font> to <font color="blue">Neutrogena </font>pursuant to a     related supply <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>ProCyte’s sales to <font color="blue">Neutrogena </font>under the supply     <font color="blue">agreement</font> for 2004 and for the year ended <font color="blue">December </font>31, 2005, were dlra1cmam553cmam999     and dlra812cmam000, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td><font color="blue">Neutrogena </font>has agreed to an extension of the     supply  <font color="blue">agreement</font>  through October 5, 2007, on terms that we regard as     <font color="blue">generally</font> favorable to us</td>
    </tr>
    <tr>
      <td>23       _________________________________________________________________       <font color="blue">Excluding </font>niche <font color="blue">marketing efforts</font>, the <font color="blue">Skin Care </font>segment targets its sales     in the US market to physicians, who then mark the <font color="blue">products up</font> for sale to     their patients</td>
    </tr>
    <tr>
      <td>No <font color="blue">single practice</font> in itself is <font color="blue">generally</font> responsible for a     <font color="blue">significant</font> <font color="blue">disproportion</font> of our sales</td>
    </tr>
    <tr>
      <td>However, a number of practices,     <font color="blue">specializing</font> in <font color="blue">hair transplant</font>s, are united under the <font color="blue">management</font> of a     single group, and this group <font color="blue">accounts</font> for a <font color="blue">disproportion</font> of our hair care     <font color="blue">products aimed at</font> the care of a scalp that has received a <font color="blue">hair transplant</font></td>
    </tr>
    <tr>
      <td><font color="blue">In the International XTRAC </font>segment (as well as in the <font color="blue">Surgical Products     </font>segment), we depend in the <font color="blue">international</font> arena for a material portion of our     sales on several key <font color="blue">distributors</font>, as for example our <font color="blue">master distributor</font> in     the  Pacific  Rim</td>
    </tr>
    <tr>
      <td>If we lose one of these <font color="blue">distributors</font>, our sales of     <font color="blue">phototherapy</font> and <font color="blue">surgical lasers</font> are likely to suffer in the short term</td>
    </tr>
    <tr>
      <td><font color="blue">In the Surgical Services </font>segment, we find that our model works best if we     have several <font color="blue">accounts</font> in a territory that have <font color="blue">sufficient volume</font> to allow us     to be <font color="blue">efficient</font> in the delivery of our services</td>
    </tr>
    <tr>
      <td>If we lose one of these     anchor  <font color="blue">accounts</font>, then we may become less <font color="blue">efficient</font> and <font color="blue">therefore less</font>     <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>We have acted as contract developer of a <font color="blue">system designed</font> to detect <font color="blue">cancerous</font>     cells in <font color="blue">human tissue</font> and act as an OEM <font color="blue">manufacture</font>r of <font color="blue">surgical lasers</font>     and/or delivery systems</td>
    </tr>
    <tr>
      <td><font color="blue">Development </font>work is <font color="blue">fraught with financial risk</font> and     technological <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>OEM work is usually limited to a contracted     period of time, at the end of <font color="blue">which there may</font> be <font color="blue">no extension</font> or renewal</td>
    </tr>
    <tr>
      <td>In     <font color="blue">either case</font>, our aim to create a <font color="blue">strategic partnership may</font> be frustrated</td>
    </tr>
    <tr>
      <td>The loss or reduction of business from any of our <font color="blue">significant</font> customers or     strategic partners in that business segment, <font color="blue">Neutrogena </font>in particular, or     the failure to develop new <font color="blue">significant</font> customers or strategic partners could     have a material adverse effect on the results of <font color="blue">operations</font> and our overall     <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We may not be able to protect our <font color="blue"><font color="blue">intellectual</font> property rights</font> outside the     <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td><font color="blue">Intellectual </font><font color="blue">property law outside</font> the <font color="blue"><font color="blue">United States</font> </font>is uncertain and in many     countries is <font color="blue">currently undergoing review</font> and revision</td>
    </tr>
    <tr>
      <td>The laws of some     countries do not protect our <font color="blue"><font color="blue">intellectual</font> property rights</font> to the <font color="blue">same extent</font>     as laws in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">intellectual</font> property rights</font> we enjoy in     one  country  or  <font color="blue">jurisdiction</font>  may  be rejected in other countries or     <font color="blue">jurisdiction</font>s, or, if recognized there, the <font color="blue">rights may</font> be <font color="blue">significant</font>ly     diluted</td>
    </tr>
    <tr>
      <td>It may be <font color="blue">necessary</font> or useful for us to <font color="blue">participate</font> in <font color="blue">proceedings</font>     to determine the validity of our foreign <font color="blue"><font color="blue">intellectual</font> property rights</font>, or     those of our <font color="blue"><font color="blue">competitor</font>s</font>, <font color="blue">which could</font> result in substantial cost and divert     our resources, efforts and <font color="blue">attention from</font> other aspects of our business</td>
    </tr>
    <tr>
      <td>If     we are unable to defend our <font color="blue"><font color="blue">intellectual</font> property rights</font> <font color="blue">international</font>ly, we     may  face increased <font color="blue">competition</font> outside the <font color="blue">United States</font>, <font color="blue">which could</font>     <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affect</font> our future business, prospects, operating     results and financial results and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Our failure to obtain or maintain <font color="blue">necessary</font> FDA <font color="blue">clearances</font> or approvals     <font color="blue">could hurt</font> our ability to distribute and market our products in the United     States</td>
    </tr>
    <tr>
      <td>Our  laser  products are considered <font color="blue">medical devices</font> and are subject to     extensive regulation in the <font color="blue"><font color="blue">United States</font> </font>and in <font color="blue">foreign countries</font> where we     intend to do business</td>
    </tr>
    <tr>
      <td>In addition, certain of our <font color="blue">skincare products</font> and     <font color="blue">product candidates may</font> be <font color="blue">regulated by</font> any of a number of divisions of the     FDA and in other <font color="blue">countries by</font> similar health and <font color="blue"><font color="blue">regulatory</font> authorities</font></td>
    </tr>
    <tr>
      <td>The FDAapstas 510(k) clearance     <font color="blue">process may</font> take from four to <font color="blue">twelve months</font>, or longer</td>
    </tr>
    <tr>
      <td>The pre-market     <font color="blue">application approval process</font> is much more costly, lengthy and uncertain</td>
    </tr>
    <tr>
      <td>It     may take one to <font color="blue">three years</font> or <font color="blue">even longer</font></td>
    </tr>
    <tr>
      <td>Delays in obtaining <font color="blue">regulatory</font>     clearance or approval <font color="blue">could <font color="blue"><font color="blue">adversely</font> affect</font></font> our revenues and <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>24       _________________________________________________________________       Although we have obtained 510(k) <font color="blue">clearances</font> for our XTRAC system for use in     <font color="blue">treating psoriasis</font>, vitiligo, atopic <font color="blue">dermatitis</font> and leukoderma, and 510(k)     <font color="blue">clearances</font> for our <font color="blue">surgical products</font>, our <font color="blue">clearances</font> can be revoked if     post-marketing data demonstrates safety issues or lack of <font color="blue">effective</font>ness</td>
    </tr>
    <tr>
      <td>Further, more stringent <font color="blue">regulatory</font> <font color="blue">requirements</font> and/or safety and quality     standards  may  be  issued in the <font color="blue">future with</font> an adverse effect on our     business</td>
    </tr>
    <tr>
      <td>Although we believe that we are in <font color="blue">compliance with</font> all material     <font color="blue">applicable regulations</font> of the FDA, <font color="blue">current regulations depend heavily on</font>     <font color="blue">administrative interpretation</font></td>
    </tr>
    <tr>
      <td>Future <font color="blue">interpretations</font> made by the FDA or     other <font color="blue">regulatory</font> bodies, with possible <font color="blue">retroactive</font> effect, may vary from     current <font color="blue">interpretations</font> and may <font color="blue"><font color="blue">adversely</font> affect</font> our business and prospects</td>
    </tr>
    <tr>
      <td>Even if we obtain the <font color="blue">necessary</font> <font color="blue">regulatory</font> approvals for our <font color="blue">phototherapy</font>     products  from foreign governments, market <font color="blue">acceptance</font> in <font color="blue">international</font>     markets may <font color="blue">depend on</font> third party <font color="blue">reimbursement</font> of participants’ costs</td>
    </tr>
    <tr>
      <td>We have introduced our XTRAC <font color="blue">system through</font> our <font color="blue">distributors</font> and to end     <font color="blue">users into markets</font> in more than 35 countries in Europe, the Middle East, the     Far East and Southeast Asia, and in Australia, South Africa and parts of     <font color="blue">Central and South America</font></td>
    </tr>
    <tr>
      <td>We cannot be certain that     our <font color="blue">distributors</font> will be successful in marketing XTRAC systems in these or     other countries or that our <font color="blue">distributors</font> will purchase more than their     <font color="blue">contractual obligations</font> or in <font color="blue">accordance with</font> our <font color="blue">expectations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Underlying </font>our approvals in a number of countries are our <font color="blue">quality systems</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">regularly audited on</font> the compliance of our <font color="blue">quality systems</font> with     applicable <font color="blue">requirements</font>, which can be extensive and complex and subject to     change due to evolving <font color="blue">interpretations</font> and changing <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td><font color="blue">Adverse     </font><font color="blue">audit findings could negatively affect</font> our ability to market our products</td>
    </tr>
    <tr>
      <td>Even  if  we  obtain  and  maintain  the  <font color="blue">necessary</font> foreign <font color="blue">regulatory</font>     <font color="blue">registrations</font>  or  approvals,  market  <font color="blue">acceptance</font>  of  our products in     <font color="blue">international</font> markets may be <font color="blue">dependent</font>, in part, upon the <font color="blue">availability</font> of     <font color="blue">reimbursement</font> within applicable healthcare payment systems</td>
    </tr>
    <tr>
      <td><font color="blue">Reimbursement     </font>and healthcare payment systems in <font color="blue">international</font> markets vary <font color="blue">significant</font>ly     by country, and include both government-sponsored healthcare and private     insurance</td>
    </tr>
    <tr>
      <td>We  may seek <font color="blue">international</font> <font color="blue">reimbursement</font> approvals for our     products, but we <font color="blue">cannot assure</font> you that any <font color="blue">such approvals will</font> be obtained     in  a  timely  manner,  if  at  all</td>
    </tr>
    <tr>
      <td>Failure to receive <font color="blue">international</font>     <font color="blue">reimbursement</font> approvals in any <font color="blue">given market could</font> have a material adverse     effect on the <font color="blue">acceptance</font> of our products in that market or others</td>
    </tr>
    <tr>
      <td>We have limited marketing experience, and our failure to build and manage     our <font color="blue">marketing force</font> or to market and distribute our products <font color="blue">effective</font>ly     will hurt our revenues and profits</td>
    </tr>
    <tr>
      <td>We  have limited marketing experience and limited <font color="blue">marketing resources</font></td>
    </tr>
    <tr>
      <td>However, we expect that we will have to expand the number of our sales and     marketing  personnel  in order to implement our <font color="blue">marketing programs</font> and     strategy so as to <font color="blue">increase <font color="blue">utilization</font></font> <font color="blue">of the XTRAC </font>system in the United     States</td>
    </tr>
    <tr>
      <td><font color="blue">Different </font><font color="blue">programs may call</font> for <font color="blue">different strategies</font> and talents</td>
    </tr>
    <tr>
      <td>While we may be able to <font color="blue">draw on currently available personnel within</font> our     <font color="blue">organization</font>, we also expect that we will have to increase the number of     <font color="blue">representatives devoted</font> to the sales and <font color="blue">marketing programs</font> and broaden,     <font color="blue">through such representatives</font>, the talents we have at our disposal</td>
    </tr>
    <tr>
      <td>In some     cases, we <font color="blue">may look outside</font> our <font color="blue">organization</font> for assistance in marketing our     products, as for example in a program to market our <font color="blue">surgical diode laser</font>     through the internet</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot predict</font> whether the anticipated sales and     <font color="blue">marketing programs</font> will be successful, either in design or <font color="blue">implementation</font></td>
    </tr>
    <tr>
      <td>In similar fashion, we <font color="blue">cannot predict</font> how successful we may be in expanding     our <font color="blue">skincare products</font> or <font color="blue">surgical services</font> in the <font color="blue">United States</font>, nor can we     predict  the  success of new skincare or <font color="blue">surgical products</font> that we may     introduce</td>
    </tr>
    <tr>
      <td>There are, for example, <font color="blue">skincare products</font> and diode and CO2     <font color="blue">lasers already</font> in the <font color="blue">market against which</font> our <font color="blue">comparable <font color="blue">products must</font></font>     compete</td>
    </tr>
    <tr>
      <td>No assurance can be given that we will be successful in marketing     and selling our skin health and <font color="blue">hair care products</font> or our diode and CO2     lasers</td>
    </tr>
    <tr>
      <td>25       _________________________________________________________________       There are <font color="blue">significant</font> risks involved in building and managing our marketing     force and marketing our products, including our ability:           ·     to hire, as needed, a sufficient number of <font color="blue">qualified marketing</font> people with     the skills and understanding to market the XTRAC system, our skincare     products and our <font color="blue">surgical products</font> services and <font color="blue">effective</font>ly;           ·     to <font color="blue">adequately train</font> our <font color="blue">marketing force</font> in the use and benefits of our     products and services, making them more <font color="blue">effective</font> promoters;           ·     to set the prices and other terms and <font color="blue">conditions</font> for <font color="blue">treatments</font> using an     XTRAC system and our <font color="blue">surgical services</font> in a <font color="blue">complex legal environment</font> so     that they will be <font color="blue">accepted as attractive</font> and <font color="blue">appropriate</font> <font color="blue"><font color="blue">alternative</font>s</font> to     <font color="blue">conventional</font> service modalities and <font color="blue">treatments</font>; and           ·     to <font color="blue">cope with employee turnover among</font> the <font color="blue">sales force</font> in the skin care     business, which is highly <font color="blue">competitive</font> for <font color="blue">talented sales representatives</font></td>
    </tr>
    <tr>
      <td>We  have  limited  experience <font color="blue">manufacturing</font> our products in commercial     quantities, <font color="blue">which could</font> <font color="blue">adversely</font> impact the <font color="blue">rate at which</font> we grow</td>
    </tr>
    <tr>
      <td>We may encounter <font color="blue">difficult</font>ies <font color="blue">manufacturing</font> our products for the following     reasons:           ·     we have limited experience <font color="blue">manufacturing</font> our products in commercial     quantities; and           ·     we will, in order to increase our <font color="blue">manufacturing</font> output <font color="blue">significant</font>ly, have     to attract and retain <font color="blue">qualified employees</font>, who are in short supply, for     assembly and testing <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Although we believe that our current <font color="blue"><font color="blue">manufacturing</font> facilities</font> are adequate     to support our commercial <font color="blue">manufacturing</font> activities for the foreseeable     future,  we  may be required to expand our <font color="blue"><font color="blue">manufacturing</font> facilities</font> to     increase capacity <font color="blue">substantially</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">provide customers with</font>     high-quality products in a <font color="blue">timely manner</font>, we may not be able to achieve     market <font color="blue">acceptance</font> for our XTRAC system, to maintain the benefits of vertical     <font color="blue">integration</font> in the delivery of our <font color="blue">surgical services</font> or to achieve market     <font color="blue">acceptance</font>  for our <font color="blue">skincare products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">inability</font> to <font color="blue">manufacture</font> or     <font color="blue">commercialize</font> our <font color="blue">devices successfully could</font> have a material adverse effect     on our revenue</td>
    </tr>
    <tr>
      <td>We may have <font color="blue">difficult</font>y managing our growth</td>
    </tr>
    <tr>
      <td>If <font color="blue">additional private carriers approve</font> favorable <font color="blue"><font color="blue">reimbursement</font> policies</font> for     psoriasis  and  our  marketing  programs  are successful in increasing     <font color="blue">utilization</font> <font color="blue">of the XTRAC </font>system, we expect to experience growth in the     number of our employees and customers and the scope of our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">growth may</font> place a strain on our <font color="blue">management</font> and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our ability to     manage this <font color="blue">growth will depend upon</font> our ability to broaden our <font color="blue">management</font>     team and our ability to attract, hire and retain <font color="blue">skilled employees</font></td>
    </tr>
    <tr>
      <td>We also     expect  that  compliance  with  the  <font color="blue">requirements</font>  of <font color="blue">governmental</font> and     quasi-<font color="blue">governmental</font> bodies will grow more complex and burdensome</td>
    </tr>
    <tr>
      <td>Our success     will  also  <font color="blue">depend on</font> the ability of our officers and <font color="blue">key employees</font> to     continue to implement and improve our operational, financial and other     systems, to manage multiple, concurrent customer relationships, to respond     to increasing compliance <font color="blue">requirements</font> and to hire, train and manage our     employees</td>
    </tr>
    <tr>
      <td>Our  future  success  is heavily <font color="blue"><font color="blue">dependent</font> upon</font> growth and     <font color="blue">acceptance</font> of our products</td>
    </tr>
    <tr>
      <td>If we <font color="blue">cannot scale</font> our business <font color="blue">appropriate</font>ly or     otherwise  adapt  to anticipated growth and <font color="blue">complexity</font> and new product     <font color="blue">introductions</font>, a key part of our <font color="blue">strategy may</font> not be successful</td>
    </tr>
    <tr>
      <td>In addition, we may acquire <font color="blue">additional companies</font> in the <font color="blue">medical products</font> and     <font color="blue">services industry</font></td>
    </tr>
    <tr>
      <td>Accordingly, in the <font color="blue">ordinary course</font> of our business, we     regularly  consider,  evaluate  and <font color="blue">enter into negotiations</font> related to     potential <font color="blue">acquisition</font> opportunities</td>
    </tr>
    <tr>
      <td>We may pay for these <font color="blue">acquisition</font>s in     cash or securities, including <font color="blue">equity securities</font>, or a <font color="blue">combination</font> of both</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that attractive <font color="blue">acquisition</font> targets will be available     <font color="blue">at reasonable prices</font> or that we will be successful in any <font color="blue">such transaction</font></td>
    </tr>
    <tr>
      <td><font color="blue">Acquisitions </font>involve a number of <font color="blue">special risks</font>, including:           ·     diversion of our <font color="blue">management</font>’s attention;           ·     <font color="blue">integration</font> of the acquired business with our business; and           ·     <font color="blue">unanticipated legal liabilities</font> and other <font color="blue">circumstances</font> or events</td>
    </tr>
    <tr>
      <td>26       _________________________________________________________________       <font color="blue">The XTRAC </font>system and other <font color="blue">laser systems</font> we <font color="blue">manufacture</font> for surgery require     specific  component  parts  that  may not be <font color="blue">readily available</font> or cost     <font color="blue">effective</font>,  which  may  <font color="blue">adversely</font>  affect  our <font color="blue"><font color="blue">competitive</font> position</font> or     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">skin care products may</font> require compounds that can be     <font color="blue">efficient</font>ly produced by a limited number of suppliers</td>
    </tr>
    <tr>
      <td><font color="blue">Production </font>of our XTRAC system requires specific component parts obtained     from our suppliers</td>
    </tr>
    <tr>
      <td><font color="blue">Production </font>of our <font color="blue">surgical <font color="blue">laser systems</font></font> requires some     component parts that will become harder to procure, as the design of the     system ages</td>
    </tr>
    <tr>
      <td>Similarly, our <font color="blue">skin care products may</font> require compounds that     can be <font color="blue">efficient</font>ly produced only by a limited number of suppliers</td>
    </tr>
    <tr>
      <td>In the     event that our suppliers cannot meet our needs, we believe that we could     find  <font color="blue">alternative</font>  suppliers</td>
    </tr>
    <tr>
      <td>However,  a  change in suppliers or any     <font color="blue">significant</font> delay in our ability to have access to <font color="blue">such resources would</font> have     a material adverse effect on our <font color="blue">delivery schedules</font>, business, operating     results and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>Our failure to respond to rapid changes in <font color="blue">technology</font> and its <font color="blue">applications</font>     and intense <font color="blue">competition</font> in the <font color="blue">medical devices</font> industry or the <font color="blue">development</font>     of  a  cure for skin <font color="blue">conditions</font> treated by our <font color="blue">products could</font> make our     <font color="blue">treatment system obsolete</font></td>
    </tr>
    <tr>
      <td>The  medical  devices  industry  is  subject  to rapid and substantial     technological <font color="blue">development</font> and product <font color="blue">innovations</font></td>
    </tr>
    <tr>
      <td>To be successful, we must     respond to new <font color="blue">development</font>s in <font color="blue">technology</font>, new <font color="blue">applications</font> of existing     <font color="blue">technology</font> and <font color="blue">new treatment methods</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">response may</font> be stymied if we     require, but cannot secure, rights to essential third-party <font color="blue">intellectual</font>     property</td>
    </tr>
    <tr>
      <td>We  compete against numerous companies offering <font color="blue">alternative</font>     <font color="blue">treatment systems</font> to ours, some of which have greater financial, marketing     and <font color="blue">technical resources</font> to utilize in pursuing technological <font color="blue">development</font> and     <font color="blue">new treatment methods</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">financial condition</font> and operating results could     be <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font> if our <font color="blue">medical devices</font> fail to <font color="blue">compete favorably with</font>     these technological <font color="blue">development</font>s, or if we fail to be <font color="blue">responsive on</font> a timely     and <font color="blue">effective</font> basis to <font color="blue"><font color="blue">competitor</font>s</font>’ new devices, <font color="blue">applications</font>, <font color="blue">treatments</font> or     <font color="blue">price strategies</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of a cure for psoriasis, vitiligo, atopic     <font color="blue">dermatitis</font> or leukoderma would eliminate the need for our XTRAC system for     these  diseases  and  would  require  us to focus on other uses of our     <font color="blue">technology</font>, which would have a material adverse effect on our business or     prospects</td>
    </tr>
    <tr>
      <td>In  addition,  <font color="blue">competition</font> in the skin health and <font color="blue">hair care markets</font> is     intense</td>
    </tr>
    <tr>
      <td>Our skincare <font color="blue"><font color="blue">competitor</font>s</font> include well-established pharmaceutical,     cosmetic and <font color="blue">healthcare companies such as</font> Obagi, La Roche Posay, Allergan,     Pevonia,  Declore and Murad</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">competitor</font>s</font> have <font color="blue">substantially</font> more     financial and other resources, larger research and <font color="blue">development</font> staffs, and     more experience and <font color="blue">capabilities</font> in <font color="blue">researching</font>, developing and testing     products in <font color="blue"><font color="blue">clinical trial</font>s</font>, in obtaining FDA and other <font color="blue">regulatory</font> approvals     and in <font color="blue">manufacturing</font>, marketing and <font color="blue">distribution</font> than we do</td>
    </tr>
    <tr>
      <td>Further, a     number  of  smaller  companies are developing or marketing <font color="blue">competitive</font>     products</td>
    </tr>
    <tr>
      <td>Our  skincare  <font color="blue"><font color="blue">competitor</font>s</font>  may  succeed  in developing and     <font color="blue">commercializing</font> products or obtaining <font color="blue">patent protection</font> or other <font color="blue">regulatory</font>     approvals  for products more <font color="blue">rapidly than</font> we can</td>
    </tr>
    <tr>
      <td>Further, <font color="blue">competitive</font>     products  may  be <font color="blue">manufacture</font>d and marketed more <font color="blue">successfully than</font> our     potential <font color="blue">skincare products</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">development</font>s could render our existing or     potential <font color="blue">skincare products</font> less <font color="blue">competitive</font> or obsolete and could have a     material adverse effect on our business, <font color="blue">financial condition</font> and results of     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>As  we  develop  <font color="blue">new products</font> or improve our <font color="blue">existing products</font>, we may     <font color="blue">accelerate</font> the <font color="blue">economic obsolescence</font> of the existing, unimproved products,     and their <font color="blue">components</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">obsolescent products</font> and related <font color="blue">components</font> may     have little to no resale value, leading to an increase in the reserves we     have against our inventory</td>
    </tr>
    <tr>
      <td>On the other side, there is a risk that the new     products or improved <font color="blue">existing products</font> may not achieve market <font color="blue">acceptance</font> and     <font color="blue">therefore also lead</font> to an increase in the <font color="blue">reserves against</font> our inventory</td>
    </tr>
    <tr>
      <td>Our products may be found defective or physicians and <font color="blue">technicians</font> may misuse     our products and <font color="blue">damages may exceed</font> our <font color="blue">insurance coverage</font></td>
    </tr>
    <tr>
      <td>One or more of our products may be found to be defective after they have     been shipped in volume, and require product <font color="blue">replacement</font></td>
    </tr>
    <tr>
      <td>Product returns and     the potential need to <font color="blue">remedy defects</font> or provide <font color="blue">replacement</font> products or     <font color="blue">parts could</font> result in substantial costs and have a material adverse effect     on  our  business  and  results  of  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">clinical testing</font>,     <font color="blue">manufacturing</font>, marketing and use of our products and <font color="blue">procedures may also</font>     expose us to <font color="blue">product <font color="blue">liability</font></font> claims</td>
    </tr>
    <tr>
      <td>In addition, the fact that we train     <font color="blue">technicians</font> whom we do not supervise in the use of our XTRAC system when     patients are treated and that we train and provide our <font color="blue">technicians</font> as part     of our <font color="blue">surgical services</font> business <font color="blue">may expose us</font> to third-party claims if     those doing the training are accused of providing inadequate training or if     a technician is accused of <font color="blue">negligently applying such training</font></td>
    </tr>
    <tr>
      <td>We presently     maintain <font color="blue"><font color="blue">liability</font> insurance with coverage limits</font> of at least dlra5cmam000cmam000 per     occurrence</td>
    </tr>
    <tr>
      <td><font color="blue">Continuing  </font><font color="blue">insurance coverage</font> may not be <font color="blue">available at</font> an     acceptable cost, if at all</td>
    </tr>
    <tr>
      <td>We may not be able to obtain <font color="blue">insurance coverage</font>     that will be adequate to satisfy any <font color="blue">liability</font> that may arise</td>
    </tr>
    <tr>
      <td><font color="blue">Regardless </font>of     merit or eventual outcome, <font color="blue">product <font color="blue">liability</font></font> claims may result in decreased     demand for a product, injury to its reputation, withdrawal of <font color="blue">clinical trial</font>     volunteers and loss of revenues</td>
    </tr>
    <tr>
      <td>As a result, <font color="blue">regardless</font> of whether we are     insured, a <font color="blue">product <font color="blue">liability</font></font> claim or product recall may result in losses     that could have a material adverse effect upon our business, financial     condition and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>27       _________________________________________________________________       If we <font color="blue">use hazardous materials</font> in a manner that causes injury or violates     laws, our business and <font color="blue">operations</font> may suffer</td>
    </tr>
    <tr>
      <td><font color="blue">Our XTRAC </font><font color="blue">system utilizes</font> a <font color="blue">xenon chloride gas mixture under high pressure</font>,     which is <font color="blue">extremely corrosive</font></td>
    </tr>
    <tr>
      <td>While methods for proper disposal and handling     of this gas are well-known, we <font color="blue">cannot completely eliminate</font> the risk of     accidental contamination, <font color="blue">which could</font> cause:           ·     an <font color="blue">interruption</font> of our research and <font color="blue">development</font> efforts;           ·     injury to our employees, physicians, <font color="blue">technicians</font> or patients <font color="blue">which could</font>     result in the payment of damages; or           ·     <font color="blue">liabilities under federal</font>, state and <font color="blue">local laws</font> and <font color="blue">regulations governing</font>     the use, storage, handling and disposal of these materials and specified     <font color="blue">waste products</font></td>
    </tr>
    <tr>
      <td>From time to time, <font color="blue">customers return</font> to us <font color="blue">surgical products</font> that appear not     to have performed to <font color="blue">specification</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">products must</font> be <font color="blue">decontaminated</font>     before being returned to us</td>
    </tr>
    <tr>
      <td>If they are not, our <font color="blue">employees may</font> be exposed     to <font color="blue">dangerous diseases</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">depend on</font> our <font color="blue">executive officers</font> and <font color="blue">key personnel</font> to implement our     business strategy and could be <font color="blue">harmed by</font> the loss of their services</td>
    </tr>
    <tr>
      <td>We believe that our growth and future <font color="blue">success will depend</font> in large part upon     the  skills  of our <font color="blue">management</font> and <font color="blue">technical team</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">competition</font> for     <font color="blue">qualified personnel</font> in the <font color="blue">laser industry</font> is intense, and the loss of our     <font color="blue">key personnel</font> or an <font color="blue">inability</font> to continue to attract, retain and motivate     <font color="blue">key personnel</font> <font color="blue">could <font color="blue"><font color="blue">adversely</font> affect</font></font> our business</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot assure</font> you that     we  will  be  able  to retain our existing <font color="blue">key personnel</font> or to attract     additional <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td>We do not have key-person life insurance on     any of our employees</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> in part upon the <font color="blue">continued service</font> and performance of:           ·     Jeffrey F O’Donnell, President and Chief Executive Officer;           ·     Dennis M McGrath, Chief Financial Officer;           ·     Michael R Stewart, Executive Vice President and Chief Operating Officer;           ·     John F Clifford, Executive Vice President Dermatology and           ·     Robin L Carmichael, Vice President - Marketing               28       _________________________________________________________________       Although we have employment <font color="blue">agreement</font>s with Mr</td>
    </tr>
    <tr>
      <td>O’Donnell, Mr</td>
    </tr>
    <tr>
      <td>McGrath, Mr</td>
    </tr>
    <tr>
      <td>Stewart, Mr</td>
    </tr>
    <tr>
      <td><font color="blue">Clifford and Ms</font></td>
    </tr>
    <tr>
      <td>Carmichael, the loss of the services of one or     more of our officers <font color="blue">could <font color="blue"><font color="blue">adversely</font> affect</font></font> our ability to develop and     introduce our <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>We may be <font color="blue">unsuccessful</font> in <font color="blue">integrating</font> the <font color="blue">operations</font> of ProCyte with our     other business segments</td>
    </tr>
    <tr>
      <td>We acquired ProCyte with the <font color="blue">following goals</font> in mind:           ·     that ProCyteapstas presence in the skin health and <font color="blue">hair care products</font> market     <font color="blue">would present</font> a <font color="blue">growth <font color="blue">opportunity</font></font> for <font color="blue">PhotoMedex </font>to market its existing     products;           ·     that the addition of ProCyteapstas sales and <font color="blue">marketing personnel would enhance</font>     our ability to market the XTRAC system;           ·     that the addition of ProCyteapstas <font color="blue">operations</font> and <font color="blue">existing cash balances would</font>     enhance PhotoMedexapstas operating results and <font color="blue">balance sheet</font>;           ·     that the <font color="blue">combination</font> of the senior <font color="blue">management</font> of ProCyte and <font color="blue">PhotoMedex </font>    <font color="blue">would allow complementary skills</font> to strengthen the overall <font color="blue">management</font> team;     and           ·     that the combined company may reap short-term cost savings and have the     <font color="blue">opportunity</font> for additional longer-term cost efficiencies, thus providing     <font color="blue">additional cash flow</font> for <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we fail to attain some     of the goals, our overall business and <font color="blue">financial health could</font> be <font color="blue">materially</font>     and <font color="blue"><font color="blue"><font color="blue">adversely</font> affect</font>ed</font></td>
    </tr>
    <tr>
      <td><font color="blue">Delaware </font>law and our charter <font color="blue">documents</font> have anti-takeover provisions that     <font color="blue">could delay</font> or <font color="blue">prevent actual</font> and potential changes in control, even if they     <font color="blue">would benefit</font> <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>We are subject to Section 203 of the <font color="blue">Delaware </font>General Corporation Law, which     prohibits a business <font color="blue">combination</font> between a <font color="blue">corporation</font> and an interested     stockholder within <font color="blue">three years</font> of the <font color="blue">stockholder becoming</font> an interested     stockholder,  except in limited <font color="blue">circumstances</font></td>
    </tr>
    <tr>
      <td>In addition, our bylaws     <font color="blue">contain certain provisions which</font> require <font color="blue">stockholders</font> &amp;apos  actions to be taken     at meetings and not <font color="blue">by written consent</font>, and also require <font color="blue">supermajority votes</font>     of  <font color="blue">stockholders</font> to amend our bylaws and to notice <font color="blue">special meetings</font> of     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>These anti-takeover provisions <font color="blue">could delay</font> or <font color="blue">prevent actual</font>     and  potential  changes  in  control,  even  if they <font color="blue">would benefit</font> our     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">Potential </font><font color="blue">fluctuations</font> in our operating results could lead to <font color="blue">fluctuations</font>     in the <font color="blue">market price</font> for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our results of <font color="blue">operations</font> are expected to fluctuate <font color="blue">significant</font>ly from     quarter-to-quarter, depending upon numerous factors, including:           ·     <font color="blue">healthcare reform</font> and <font color="blue"><font color="blue">reimbursement</font> policies</font>;           ·     demand for our products;           ·     changes in our <font color="blue">pricing policies</font> or those of our <font color="blue"><font color="blue">competitor</font>s</font>;           ·     increases in our <font color="blue">manufacturing</font> costs;           ·     the number, timing and significance of <font color="blue">product enhancements</font> and new product     <font color="blue"><font color="blue">announcements</font> by ourselves</font> and our <font color="blue"><font color="blue">competitor</font>s</font>;           ·     the <font color="blue">termination</font> or expiration of <font color="blue">significant</font> royalty-generating licensing     contracts to which we are party;           ·     the expiration of certain of our <font color="blue">key patents</font>;           ·     our ability to develop, introduce and <font color="blue">market new</font> and <font color="blue">enhanced versions</font> of     our <font color="blue">products on</font> a <font color="blue">timely basis</font> considering, among other things, delays     <font color="blue">associated with</font> the FDA and other <font color="blue">regulatory</font> approval processes and the     timing and results of future <font color="blue"><font color="blue">clinical trial</font>s</font>; and           ·     product quality problems, personnel changes, and changes in our business     strategy</td>
    </tr>
    <tr>
      <td>Our quarter-to-quarter operating results <font color="blue">could also</font> be <font color="blue">affected by</font> the     timing and usage of individual <font color="blue">laser units</font> in the treatment of patients,     since our <font color="blue">revenue model</font> for the <font color="blue">excimer laser system</font> for the treatment of     <font color="blue">psoriasis patients</font> and for our <font color="blue">surgical services</font> is <font color="blue">based on</font> a <font color="blue">payment per</font>     usage plan</td>
    </tr>
    <tr>
      <td>The  market  price for our <font color="blue">common stock</font> could fluctuate due to various     factors</td>
    </tr>
    <tr>
      <td>These factors include:           ·     <font color="blue">announcements</font> related to our efforts to secure favorable <font color="blue">reimbursement</font>     <font color="blue">policies from private carriers concerning</font> the treatment of <font color="blue">psoriasis with</font>     the XTRAC system or to our efforts to <font color="blue">increase <font color="blue">utilization</font></font> of the XTRAC;           ·     <font color="blue">acquisition</font>-related <font color="blue">announcements</font>;           ·     <font color="blue">announcements</font> by us or our <font color="blue"><font color="blue">competitor</font>s</font> of new contracts, technological     <font color="blue">innovations</font> or <font color="blue">new products</font>;           ·     changes in <font color="blue">government regulations</font>;           ·     <font color="blue">fluctuations</font> in our quarterly and annual operating results; and           ·     general market <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>In  addition,  the  stock  markets  have, in <font color="blue">recent years</font>, experienced     <font color="blue">significant</font> price <font color="blue">fluctuations</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">fluctuations</font> often have <font color="blue">been unrelated</font>     to  the operating performance of the <font color="blue">specific companies whose stock</font> is     traded</td>
    </tr>
    <tr>
      <td>Market <font color="blue">fluctuations</font>, as well as economic <font color="blue">conditions</font>, have <font color="blue">adversely</font>     affected, and <font color="blue">may continue</font> to <font color="blue"><font color="blue">adversely</font> affect</font>, the <font color="blue">market price</font> of our     <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">pay dividends on</font> our <font color="blue">common stock</font> may be limited</td>
    </tr>
    <tr>
      <td>We do not expect to pay any <font color="blue">cash dividends</font> in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>We     intend to retain earnings, if any, to <font color="blue">provide funds</font> for the expansion of our     business</td>
    </tr>
    <tr>
      <td><font color="blue">Limitations </font>on director <font color="blue">liability</font> may discourage <font color="blue">stockholders</font> from bringing     <font color="blue">suit against</font> a director</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">certificate</font>  of in<font color="blue">corporation</font> provides, as permitted by governing     <font color="blue">Delaware </font>law, that a director shall not be <font color="blue">personally liable</font> to us or our     <font color="blue">stockholders</font>  for  monetary  damages for breach of <font color="blue"><font color="blue">fiduciary</font> duty as</font> a     director,  with  certain  <font color="blue">exceptions</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions may discourage</font>     <font color="blue">stockholders</font> from bringing <font color="blue">suit against</font> a director for breach of <font color="blue">fiduciary</font>     duty and may reduce the likelihood of derivative <font color="blue">litigation</font> brought by     <font color="blue">stockholders</font> on our <font color="blue">behalf against</font> a director</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">certificate</font>     of  in<font color="blue">corporation</font>  and <font color="blue">bylaws provide</font> for <font color="blue">mandatory indemnification</font> of     <font color="blue">directors</font> and officers to the <font color="blue">fullest extent permitted by</font> <font color="blue">Delaware </font>law</td>
    </tr>
    <tr>
      <td>In     addition,  we have agreed to indemnify the past and present <font color="blue">directors</font>,     officers and employees of ProCyte for certain matters, to the <font color="blue">same extent</font>     <font color="blue">such individuals</font> are <font color="blue">indemnified by</font> ProCyte, for a period of six years     following the <font color="blue">effective</font> date of the merger</td>
    </tr>
  </tbody>
</table>